Cisplatin-based chemotherapy with or without bevacizumab for Chinese postmenopausal women with advanced cervical cancer: a retrospective observational study
Abstract Background The purpose of this study was to assess the efficacy and safety of cisplatin-based chemotherapy with or without bevacizumab (BEV) in Chinese women with advanced cervical cancer (ACC). Methods For this observational study, we analysed the data of 316 Chinese women with ACC who wer...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2020-05-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s12885-020-06854-w |
| _version_ | 1830491924954349568 |
|---|---|
| author | Xiaoli He Jun Liu Li Xiao Mingdong Zhao Tingting Su Tiejian Liu Guowei Han Yue Wang |
| author_facet | Xiaoli He Jun Liu Li Xiao Mingdong Zhao Tingting Su Tiejian Liu Guowei Han Yue Wang |
| author_sort | Xiaoli He |
| collection | DOAJ |
| description | Abstract Background The purpose of this study was to assess the efficacy and safety of cisplatin-based chemotherapy with or without bevacizumab (BEV) in Chinese women with advanced cervical cancer (ACC). Methods For this observational study, we analysed the data of 316 Chinese women with ACC who were treated at the Henan provincial people’s hospital between Jan 1, 2014, and Dec 31, 2018, with cisplatin-based chemotherapy plus BEV (CB) or cisplatin-based chemotherapy alone (CA) until disease progression, unacceptable toxicity, or death. The co-primary endpoints were overall survival (OS) and progression-free survival (PFS); the secondary endpoint was the occurrence of adverse events (AEs). Results A total of 264 patients with ACC were included in the assessment (CB, n = 130 and CA, n = 134). At a median follow-up of 38 months (IQR 36–40), the median OS in the CB cohort was significantly longer than that in the CA cohort (hazard ratio [HR] 1.21, 95% confidence interval[CI] 1.14–1.73; p = 0.002); additionally, the median PFS was 345 days (95% CI, 318–372) for CB and 261 days (95% CI, 165–357) for CA(HR 1.61, 95% CI 1.12–2.17; p = 0.000). Significant differences were noted between groups in terms of thrombosis/embolism, neutropenia, and febrile neutropenia. Conclusions In Chinese women with ACC, cisplatin-based chemotherapy plus BEV is associated with improved survival compared to cisplatin-based chemotherapy alone. This finding suggests a positive survival benefit of anti-angiogenesis therapy in this population. |
| first_indexed | 2024-12-21T20:20:51Z |
| format | Article |
| id | doaj.art-86e1d39fe8704218936de74f288bd0c5 |
| institution | Directory Open Access Journal |
| issn | 1471-2407 |
| language | English |
| last_indexed | 2024-12-21T20:20:51Z |
| publishDate | 2020-05-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj.art-86e1d39fe8704218936de74f288bd0c52022-12-21T18:51:30ZengBMCBMC Cancer1471-24072020-05-012011810.1186/s12885-020-06854-wCisplatin-based chemotherapy with or without bevacizumab for Chinese postmenopausal women with advanced cervical cancer: a retrospective observational studyXiaoli He0Jun Liu1Li Xiao2Mingdong Zhao3Tingting Su4Tiejian Liu5Guowei Han6Yue Wang7Department of Gynaecology, Henan Provincial People’s Hospital, People’s Hospital of Zhengzhou University, People’s Hospital of Henan UniversityDepartment of Gynaecology, The First Affiliated Hospital, Sun Yat-sen UniversityDepartment of Gynaecology and Obstetrics, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and TechnologyDepartment of Orthopaedics, Jinshan Hospital, Fudan UniversityDepartment of Gynaecology, The Obstetrics and Gynecology Hospital of Fudan UniversityDepartment of Neurosurgery, The Third Affiliated Hospital of Southern Medical UniversityDepartment of Orthopaedics, The First Affiliated Hospital, Sun Yat-sen UniversityDepartment of Gynaecology, Henan Provincial People’s Hospital, People’s Hospital of Zhengzhou University, People’s Hospital of Henan UniversityAbstract Background The purpose of this study was to assess the efficacy and safety of cisplatin-based chemotherapy with or without bevacizumab (BEV) in Chinese women with advanced cervical cancer (ACC). Methods For this observational study, we analysed the data of 316 Chinese women with ACC who were treated at the Henan provincial people’s hospital between Jan 1, 2014, and Dec 31, 2018, with cisplatin-based chemotherapy plus BEV (CB) or cisplatin-based chemotherapy alone (CA) until disease progression, unacceptable toxicity, or death. The co-primary endpoints were overall survival (OS) and progression-free survival (PFS); the secondary endpoint was the occurrence of adverse events (AEs). Results A total of 264 patients with ACC were included in the assessment (CB, n = 130 and CA, n = 134). At a median follow-up of 38 months (IQR 36–40), the median OS in the CB cohort was significantly longer than that in the CA cohort (hazard ratio [HR] 1.21, 95% confidence interval[CI] 1.14–1.73; p = 0.002); additionally, the median PFS was 345 days (95% CI, 318–372) for CB and 261 days (95% CI, 165–357) for CA(HR 1.61, 95% CI 1.12–2.17; p = 0.000). Significant differences were noted between groups in terms of thrombosis/embolism, neutropenia, and febrile neutropenia. Conclusions In Chinese women with ACC, cisplatin-based chemotherapy plus BEV is associated with improved survival compared to cisplatin-based chemotherapy alone. This finding suggests a positive survival benefit of anti-angiogenesis therapy in this population.http://link.springer.com/article/10.1186/s12885-020-06854-wBevacizumabCervical cancerChemotherapyOverall survivalProgression-free survival |
| spellingShingle | Xiaoli He Jun Liu Li Xiao Mingdong Zhao Tingting Su Tiejian Liu Guowei Han Yue Wang Cisplatin-based chemotherapy with or without bevacizumab for Chinese postmenopausal women with advanced cervical cancer: a retrospective observational study BMC Cancer Bevacizumab Cervical cancer Chemotherapy Overall survival Progression-free survival |
| title | Cisplatin-based chemotherapy with or without bevacizumab for Chinese postmenopausal women with advanced cervical cancer: a retrospective observational study |
| title_full | Cisplatin-based chemotherapy with or without bevacizumab for Chinese postmenopausal women with advanced cervical cancer: a retrospective observational study |
| title_fullStr | Cisplatin-based chemotherapy with or without bevacizumab for Chinese postmenopausal women with advanced cervical cancer: a retrospective observational study |
| title_full_unstemmed | Cisplatin-based chemotherapy with or without bevacizumab for Chinese postmenopausal women with advanced cervical cancer: a retrospective observational study |
| title_short | Cisplatin-based chemotherapy with or without bevacizumab for Chinese postmenopausal women with advanced cervical cancer: a retrospective observational study |
| title_sort | cisplatin based chemotherapy with or without bevacizumab for chinese postmenopausal women with advanced cervical cancer a retrospective observational study |
| topic | Bevacizumab Cervical cancer Chemotherapy Overall survival Progression-free survival |
| url | http://link.springer.com/article/10.1186/s12885-020-06854-w |
| work_keys_str_mv | AT xiaolihe cisplatinbasedchemotherapywithorwithoutbevacizumabforchinesepostmenopausalwomenwithadvancedcervicalcanceraretrospectiveobservationalstudy AT junliu cisplatinbasedchemotherapywithorwithoutbevacizumabforchinesepostmenopausalwomenwithadvancedcervicalcanceraretrospectiveobservationalstudy AT lixiao cisplatinbasedchemotherapywithorwithoutbevacizumabforchinesepostmenopausalwomenwithadvancedcervicalcanceraretrospectiveobservationalstudy AT mingdongzhao cisplatinbasedchemotherapywithorwithoutbevacizumabforchinesepostmenopausalwomenwithadvancedcervicalcanceraretrospectiveobservationalstudy AT tingtingsu cisplatinbasedchemotherapywithorwithoutbevacizumabforchinesepostmenopausalwomenwithadvancedcervicalcanceraretrospectiveobservationalstudy AT tiejianliu cisplatinbasedchemotherapywithorwithoutbevacizumabforchinesepostmenopausalwomenwithadvancedcervicalcanceraretrospectiveobservationalstudy AT guoweihan cisplatinbasedchemotherapywithorwithoutbevacizumabforchinesepostmenopausalwomenwithadvancedcervicalcanceraretrospectiveobservationalstudy AT yuewang cisplatinbasedchemotherapywithorwithoutbevacizumabforchinesepostmenopausalwomenwithadvancedcervicalcanceraretrospectiveobservationalstudy |